First patients dosed in groundbreaking Alpha-1 therapy trial

NCT ID NCT07431112

Recruiting now Disease control Sponsor: AIRNA Corporation Source: ClinicalTrials.gov ↗

Summary

This is the first study in people to test a new drug called AIR-001 for Alpha-1 Antitrypsin Deficiency (AATD). The main goal is to see if the treatment, given as an injection under the skin, is safe and how the body processes it. The study will enroll 54 adults with a specific genetic form of AATD to test different doses.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Clinical Study Center
RECRUITING

Melbourne, Australia
Clinical Study Center
RECRUITING

Tbilisi, Georgia
Clinical Study Center
RECRUITING

London, United Kingdom

Conditions

Explore the condition pages connected to this study.

ALPHA 1-ANTITRYPSIN DEFICIENCY